Jun Jun Liu

US Patent:

6566541, May 20, 2003

Filed:

Mar 21, 2001

Appl. No.:

09/813555

Inventors:

Jun O. Liu - Cambridge MA
Eric C. Griffith - Somerville MA
Zhuang Su - Cambridge MA

Assignee:

Massachusetts Institute of Technology - Cambridge MA

International Classification:

C07D30308

US Classification:

549551, 549554, 549555, 549556, 549558, 549559, 549560, 514475

Abstract:

Novel compounds that are anti-angiogenic or immunosuppressive are described. Also described are methods for determining if an animal is at risk for a disease involving abnormal angiogenesis or an immune reaction resulting in pathology comprising evaluating an aspect of MetAP2 metabolism or structure; methods for identifying agents that are anti-angiogenic or immunosuppressive comprising evaluating the effect of the agent on an aspect of MetAP2 metabolism; methods for treating a cell having an abnormality in metabolism or structure of MetAP2; and methods for treating abnormal angiogenesis or an immune reaction which results in pathology in an animal. Pharmaceutical compositions are also provided.

US Patent:

6686450, Feb 3, 2004

Filed:

Jun 17, 1999

Appl. No.:

09/335011

Inventors:

Jun O. Liu - Cambridge MA
Luo Sun - Watertown MA

Assignee:

Massachusetts Institute of Technology - Cambridge MA

International Classification:

A61K 3816

US Classification:

530352, 530350

Abstract:

The present invention provides novel immunosuppressive agents. In particular, the invention provides immunosuppressive agents that bind calcineurin and/or that inhibit interaction between calcineurin and NF-AT. The invention also provides analogs of these agents, nucleic acids encoding the agents and/or their analogs, gene therapy vectors, etc. , and methods of making and using them.

US Patent:

6920398, Jul 19, 2005

Filed:

Jun 10, 2002

Appl. No.:

10/165946

Inventors:

Jun S. Liu - Weston MA, US
Zhaohui Steve Qin - Somerville MA, US
Tianhua Niu - West Roxbury MA, US

Assignee:

President and Fellows of Harvard College - Cambridge MA

International Classification:

G06F019/00

US Classification:

702 20

Abstract:

Haplotypes for phased genotypic information are determined from unphased genotypic information. One exemplary method includes separating a dataset that includes genotypic information for a plurality of markers for each of a plurality of individuals into subdatasets, each subdataset including the genotypic information for a subset of the plurality of markers; for each subdataset, identifying haplotypes compatible with marker information for each marker of the subset and for each individual of the plurality; and for each individual, assembling the haplotypes from each of the subsets to provide the individual's haplotype with respect to the plurality of markers.

US Patent:

59288680, Jul 27, 1999

Filed:

Apr 25, 1997

Appl. No.:

8/845674

Inventors:

Jun Liu - Cambridge MA
Edward J. Licitra - Somerset NJ

Assignee:

Massachusetts Institute of Technology - Cambridge MA

International Classification:

C12Q 168
C07H 2104
C12N 1500

US Classification:

435 6

Abstract:

Methods and a kit are provided for characterizing small molecules from a library of small molecules or alternatively identifying protein targets to which known small molecules bind. The methods include forming hybrid ligand in which at least one ligand is a small molecule. The hybrid ligand is introduced into cells that in turn contain a first and a second expression vector. Each expression vector includes DNA for expressing a hybrid protein that encodes a target protein linked to a coding sequence for a transcriptional module. The cells further contains a reporter gene, the expression of which is conditioned on the proximity of the first and second hybrid proteins to each other, an event that occurs only if the hybrid ligand binds to target sites on both hybrid proteins. Those cell which express the reporter gene are selected and the unknown small molecule or the unknown hybrid protein is identified.

US Patent:

6207704, Mar 27, 2001

Filed:

Jun 8, 1998

Appl. No.:

9/093448

Inventors:

Jun O. Liu - Cambridge MA
Eric C. Griffith - Somerville MA
Zhuang Su - Cambridge MA

Assignee:

Massachusetts Institute of Technology - Cambridge MA

International Classification:

A61K31/336
7
C07D303/04

US Classification:

514475

Abstract:

Novel compounds that are anti-angiogenic or immunosuppressive are described. Also described are methods for determining if an animal is at risk for a disease involving abnormal angiogenesis or an immune reaction resulting in pathology comprising evaluating an aspect of MetAP2 metabolism or structure; methods for identifying agents that are anti-angiogenic or immunosuppressive comprising evaluating the effect of the agent on an aspect of MetAP2 metabolism; methods for treating a cell having an abnormality in metabolism or structure of MetAP2; and methods for treating abnormal angiogenesis or an immune reaction which results in pathology in an animal. Pharmaceutical compositions are also provided.

US Patent:

53626290, Nov 8, 1994

Filed:

Aug 5, 1991

Appl. No.:

7/740175

Inventors:

Stuart L. Schreiber - Boston MA
Jeffrey S. Friedman - Portola Valley CA
Irving L. Weissman - Stanford CA
Jun Liu - Somerville MA

Assignee:

President and Fellows of Harvard College - Cambridge MA
Board of Trustees of the Leland Stanford Junior University - Palo Alto CA

International Classification:

C12Q 142
C12Q 100
G01N 3353
A61K 3702

US Classification:

435 21

Abstract:

A method of evaluating the immunosuppressive activity of a compound including contacting the compound with calcineurin and determining the ability of the compound to bind to the calcineurin. The ability to bind to the calcineurin is positively correlated to the immunosuppressive activity of the compound.

US Patent:

20190203301, Jul 4, 2019

Filed:

Jan 28, 2019

Appl. No.:

16/259419

Inventors:

- Basel, CH
HUAIXIANG HAO - MALDEN MA, US
MINDY HSIN-L HSIEH - SAN DIEGO CA, US
XIAOMO JIANG - Boston MA, US
JUN LIU - SAN DIEGO CA, US
NICHOLAS NG - SAN DIEGO CA, US

International Classification:

C12Q 1/6886
G01N 33/574
A61K 31/497

Abstract:

Disclosed are biomarkers, methods and assay for the identification of cancer patients who are predicted to benefit from the therapeutic administration of Wnt antagonist. The biomarkers include detection of RNF43 and ZNRF3 gene deletion, reduced RNF43 and ZNRF3 mRNA expression, reduced RNF43 and ZNRF3 protein expression, RNF43 and ZNRF3 inactivation mutation, phosphorylated LRP6, phophorylated Dishevelleds, and the expression of Frizzleds. These biomarkers can be associated with the better outcome for cancer patients treated with Wnt pathway inhibitors.

US Patent:

20180344738, Dec 6, 2018

Filed:

Apr 26, 2018

Appl. No.:

15/963816

Inventors:

- Basel, CH
Frada BERENSHTEYN - Woburn MA, US
Xueshi HAO - San Diego CA, US
Timothy HOFFMAN - San Diego CA, US
Qihui JIN - San Diego CA, US
Arnaud LACOSTE - Cambridge MA, US
Cameron LEE - Cambridge MA, US
Jun LIU - San Diego CA, US
Yahu LIU - San Diego CA, US
Juergen Klaus MAIBAUM - Basel, CH
Tingting MO - Saratoga CA, US
Jianfeng PAN - San Diego CA, US
Xin QU - Cambridge MA, US
Jan TCHORZ - Basel, CH
Yun Feng XIE - San Diego CA, US
Shanshan YAN - San Diego CA, US
Yefen ZOU - San Diego CA, US

International Classification:

A61K 31/519
A61K 9/00
A61K 31/4375
A61K 31/506
A61K 31/47

Abstract:

The present invention is related to 6-6 Fused Bicyclic Heteroaryl Compounds of the Formula A2 or A1 and their Use as LATS Inhibitors, or a salt, stereoisomer or pharmaceutical composition thereof; wherein the variables are as defined herein.The present invention further relates to a method of LATS inhibition in a cell population using a compound of Formula A1, or a salt, stereoisomer or pharmaceutical composition thereof. The present invention further provides a method for manufacturing compounds of the invention, and its therapeutic uses. The invention further provides methods to their preparation, to their medical use, their use in the treatment and management of diseases or disorders.